Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT-UGT1A1-AAV8-02 in Crigler-Najjar Syndrome Type I
NCT06641154Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of unoparvovec in Crigler-Najjar syndrome type I (CNS1). Started Nov 2024; status: recruiting.
02
Drugs
unoparvovec
03
Conditions
Crigler-Najjar syndrome type I (CNS1)
Beyond the preview
Go deeper on NCT06641154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641154.